CFC supports greater transparency for prescription drug pricing (SB 17)
SB 17 (Hernandez) will promote transparency by requiring pharmaceutical companies to give prior notice to purchasers before raising prices, and to provide the state with an explanation for a drug’s price increase.
CFC Letters
- 9/11/17 Assembly Floor Alert
- 6/19/17 letter to Assembly Health committee
- 5/22/17 letter to Senate Appropriations
- 4/3/17 letter of support
Tags: 2017 legislation, Big Pharma, drug prices, SB 17, transparency